All News

Galindo hopes that less patients will be diagnosed with advanced chronic kidney disease if we use the right glucose-lowering agents in the earliest stages.

Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses next steps in potential future research avenues following the results of her analysis into the risk of hematuria and proteinuria associated with rosuvastatin use.

Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.

Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses the results of her research regarding the risks of hematuria and proteinuria with rosuvastatin use.

Galindo explained how the use of glucose-lowering agents in patients with diabetes and low eGFR improved patient care.

The FDA is currently reviewing a New Drug Application for vadadustat in this patient population, and a Prescription Drug User Fee Act date has been set for March 29, 2022.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses how targeted therapies are impacting the treatment of NETs.

Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.

Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.

Galindo gave a general overview of his session and explained the new standards of care for chronic kidney disease which he has felt made a great impact on the field.

Mei Ka Fong, PharmD, BCOP, said sunitinib was the first targeted therapy for NETs, although other targeted agents are being investigated.

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, addresses the questions surrounding the efficacy of perioperative octreotide treatment for patients experiencing a carcinoid crisis.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses how CBD and cannabinol can offer potential treatment options as more research is being brought to the forefront on these as integrative medicine.

Aducanumab-avwa is a monoclonal antibody that is the first treatment of its class designed to target the amyloid β protein, a biomarker of Alzheimer disease and other dementias.

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.

NETs can occur almost anywhere in the body, although they are most common in the gastrointestinal tract and lungs.

Pharmacy managers must be transparent and should work to establish an environment where people want to trust one another and feel good about doing so.

Results of a study by the American Heart Association show a genetic predisposition may lead to an association between sleeplessness and brain bleeding.

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses his presentation at the 2021 NANETS Virtual Symposium on a prospective study of carcinoid crisis with no perioperative octreotide.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses how communication plays a huge role in treatment of neuroendocrine tumors in large cancer centers.

In a report, the World Health Organization and a partner ask developers, funders, and investigators to accelerate developing a vaccination.

The investigators caution that the quality of the evidence is variable and an optimal formulation or dose remains unknown.

The difference between individuals who were vaccinated and had the infection were higher at different intervals than for those who were unvaccinated.

A new poll shows that this year 64% of individuals between aged 50 and 64 years say they already got or are likely to get their influenza shots up from 54% last year.

Preparation H works by temporarily narrowing the blood vessels in the area, which decreases swelling and discomfort caused by hemorrhoids.

Dupilumab is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

An ectopic pregnancy occurs when a fertilized egg implants and grows outside the main cavity of the uterus.

The FDA also granted Priority Review designation for the toripalimab BLA and set a Prescription Drug User Fee Act action date for April 2022; however, the FDA is not currently planning to hold an advisory committee meeting to discuss the application.

In addition to the prevention of disease in children, COVID-19 vaccination can also limit disruptions in school attendance so that children can participate safely in school and other activities.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses why integrative treatment can help physicians personalize treatments for individuals with NETs and why it is beneficial to improve the quality of life for them.